journal article·2019-05-28

Gold Cube-in-Cube Based Oxygen Nanogenerator: A Theranostic Nanoplatform for Modulating Tumor Microenvironment for Precise Chemo-Phototherapy and Multimodal Imaging

Xing Zhang, Zhongqian Xi, Jeremiah Ong’achwa Machuki, Jianjun Luo, Dongzhi Yang, Jingjing Li, Weibing Cai, Yun Yang, Lijie Zhang, Jiangwei Tian, Kaijin Guo, Yanyan Yu, Fenglei Gao

ACS Nano· Volume 13· Issue 5
Publisher page

Abstract

Engineering a versatile oncotherapy nanoplatform integrating both diagnostic and therapeutic functions has always been an intractable challenge in targeted cancer treatment. Herein, to actualize the theme of precise medicine, a nanoplatform is developed by anchoring Mn-Cdots to doxorubicin (DOX)-loaded mesoporous silica-coated gold cube-in-cubes core/shell nanocomposites and further conjugating them to a Arg-Gly-Asp (RGD) peptide (denoted as RGD-CCmMC/DOX) to achieve an active-targeting effect. Under 635 nm irradiation, the nanoplatform acts as oxygen nanogenerator that produces O2 in situ and amplifies the content of singlet oxygen (1O2) in the hypoxic tumor microenvironment (TME), which has been demonstrated to attenuate tumor hypoxia and synchronously enhance photodynamic efficacy. Moreover, the gold cube-in-cube core in this work has been proven as a photothermal agent for hyperthermia, which exhibits a favorable photothermal effect with a 65.6% calculated photothermal conversion efficiency under 808 nm irradiation. In addition, the nanoplatform achieves heat- and pH-sensitive drug release with precise control to specific-tumor sites, executing combined chemo-phototherapy functions. Besides, it functions as a multimodal bioimaging agent of photothermal, fluorescence, and magnetic resonance imaging for the accurate diagnosis and guidance of therapy. As validated by in vivo and in vitro assays, the TME-responsive nanoplatform is highly biocompatible and effectively obliterates 4T1 tumor xenografts on nude mice after triple-synergetic treatment. This work presents a rational design of versatile nanoplatforms, which modulate the TME to enable high therapeutic performance and multiplexed imaging, which provides an innovative paradigm for targeted tumor therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221002, PR China

Institute of Orthopedics, Department of Orthopedics, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, PR China

Nanomaterials and Chemistry Key Laboratory, Wenzhou University, Wenzhou, Zhejiang 325027, PR China

School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, PR China

Funding

Natural Science Foundation of Jiangsu Province · China Postdoctoral Science Foundation · National Natural Science Foundation of China · Health Department of Jiangsu Province · Jiangsu Province Postdoctoral Science Foundation · Science and Technique Development Foundation in Jiangsu Province

References (72)

Show source-provided references
1. 10.1021/cr500419810.1021/cr5004198 ↗
2. 10.1039/C6CS00458J10.1039/C6CS00458J ↗
3. 10.1021/acsnano.6b0004310.1021/acsnano.6b00043 ↗
4. 10.1021/acsnano.7b0134610.1021/acsnano.7b01346 ↗
5. 10.1021/acsnano.7b0473610.1021/acsnano.7b04736 ↗
6. 10.1002/smll.20140214510.1002/smll.201402145 ↗
7. 10.1039/C5NR01744K10.1039/C5NR01744K ↗
8. 10.1002/adfm.20180311810.1002/adfm.201803118 ↗
9. 10.1016/j.jconrel.2015.04.02110.1016/j.jconrel.2015.04.021 ↗
10. 10.1002/adfm.20160559210.1002/adfm.201605592 ↗
11. 10.1002/adma.20170632010.1002/adma.201706320 ↗
12. 10.1021/acsami.6b0609910.1021/acsami.6b06099 ↗
13. 10.1038/s41467-018-03473-910.1038/s41467-018-03473-9 ↗
14. 10.1021/nn102336310.1021/nn1023363 ↗
15. 10.1002/adfm.20170682710.1002/adfm.201706827 ↗
16. 10.1002/adma.20160248610.1002/adma.201602486 ↗
17. 10.1021/nl201400z10.1021/nl201400z ↗
18. 10.1021/acsami.6b0457910.1021/acsami.6b04579 ↗
19. 10.1021/acs.chemmater.5b0374910.1021/acs.chemmater.5b03749 ↗
20. 10.1002/smll.20100013410.1002/smll.201000134 ↗
21. 10.1021/acs.nanolett.6b0427110.1021/acs.nanolett.6b04271 ↗
22. 10.1002/smll.20080020710.1002/smll.200800207 ↗
23. 10.1021/acs.chemmater.7b0022810.1021/acs.chemmater.7b00228 ↗
24. 10.1039/C6CS00616G10.1039/C6CS00616G ↗
25. 10.1021/ja410828710.1021/ja4108287 ↗
26. 10.1002/adfm.20170637510.1002/adfm.201706375 ↗
27. 10.1038/nrc136710.1038/nrc1367 ↗
28. 10.1016/j.biomaterials.2018.04.05110.1016/j.biomaterials.2018.04.051 ↗
29. 10.1158/0008-5472.CAN-10-426110.1158/0008-5472.CAN-10-4261 ↗
30. 10.1002/adfm.20180490110.1002/adfm.201804901 ↗
31. 10.1038/nrc239710.1038/nrc2397 ↗
32. 10.1002/adfm.20160067610.1002/adfm.201600676 ↗
33. 10.1002/adma.20140514110.1002/adma.201405141 ↗
34. 10.1002/adma.20150461710.1002/adma.201504617 ↗
35. 10.1021/acsnano.6b0415610.1021/acsnano.6b04156 ↗
36. 10.1002/adma.20170609010.1002/adma.201706090 ↗
37. 10.1016/j.biomaterials.2015.10.04810.1016/j.biomaterials.2015.10.048 ↗
38. 10.1016/j.addr.2013.08.00510.1016/j.addr.2013.08.005 ↗
39. 10.7150/thno.786910.7150/thno.7869 ↗
40. 10.1021/acsami.6b1137810.1021/acsami.6b11378 ↗
41. 10.1021/jacs.6b0178410.1021/jacs.6b01784 ↗
42. 10.1634/theoncologist.9-90005-3110.1634/theoncologist.9-90005-31 ↗
43. 10.1111/j.1742-7843.2007.00196.x10.1111/j.1742-7843.2007.00196.x ↗
44. 10.1002/btpr.5610.1002/btpr.56 ↗
45. 10.1002/adfm.20160098510.1002/adfm.201600985 ↗
46. Shirasu N. · Anticancer Res. · 2013 · 33 · 2823
47. 10.1016/j.addr.2003.07.01410.1016/j.addr.2003.07.014 ↗
48. 10.1016/j.ccr.2009.10.01310.1016/j.ccr.2009.10.013 ↗
49. 10.1021/acs.analchem.7b0055410.1021/acs.analchem.7b00554 ↗
50. 10.1038/bjc.2014.4910.1038/bjc.2014.49 ↗
51. 10.1038/srep2122510.1038/srep21225 ↗
52. 10.1016/j.jconrel.2014.12.01810.1016/j.jconrel.2014.12.018 ↗
53. 10.1002/smll.20080020710.1002/smll.200800207 ↗
54. 10.1021/nn102237c10.1021/nn102237c ↗
55. 10.1002/smll.20130225210.1002/smll.201302252 ↗
56. 10.1021/acsnano.5b0220710.1021/acsnano.5b02207 ↗
57. 10.1021/acsami.6b0085310.1021/acsami.6b00853 ↗
58. 10.1021/nn506516p10.1021/nn506516p ↗
59. 10.1038/nm.339410.1038/nm.3394 ↗
60. 10.1016/j.canlet.2006.10.02910.1016/j.canlet.2006.10.029 ↗
61. 10.1002/smll.20170307710.1002/smll.201703077 ↗
62. 10.1007/s10934-016-0296-710.1007/s10934-016-0296-7 ↗
63. 10.1021/la400479n10.1021/la400479n ↗
64. 10.1021/mp400751g10.1021/mp400751g ↗
65. 10.1039/C4NR00708E10.1039/C4NR00708E ↗
66. 10.1016/j.ccr.2009.10.01310.1016/j.ccr.2009.10.013 ↗
67. 10.1161/01.RES.0000171756.13554.4910.1161/01.RES.0000171756.13554.49 ↗
68. 10.1021/jp981996r10.1021/jp981996r ↗
69. 10.1021/acsbiomaterials.8b0111010.1021/acsbiomaterials.8b01110 ↗
70. 10.1021/acsami.6b1387610.1021/acsami.6b13876 ↗
71. 10.1021/acsnano.5b0450110.1021/acsnano.5b04501 ↗
72. 10.1039/C7SC00700K10.1039/C7SC00700K ↗